Alexander Arrow

LASIK without lasers.

Paragonix Technologies is a rapidly growing medical device manufacturer that designs, manufactures, and sells organ transplant transport devices. Our dynamic team is committed to improving the lives of transplant patients by providing advanced technologies to ensure optimal preservation for donor organs on the journey to their ultimate recipients. Our primary offices are located in Cambridge, MA.

Medcura, Inc. has developed an advanced wound care platform that can be used across a broad spectrum of clinical and non-clinical settings. By making molecular modifications to natural biopolymers, Medcura’s patented approach provides rapid hemostasis in a clean, safe healing environment. The company has achieved milestones such as 3 FDA Clearances, 6 issued patents, and 7 peer-reviewed publications.

LASIK without lasers.

Paragonix Technologies is a rapidly growing medical device manufacturer that designs, manufactures, and sells organ transplant transport devices. Our dynamic team is committed to improving the lives of transplant patients by providing advanced technologies to ensure optimal preservation for donor organs on the journey to their ultimate recipients. Our primary offices are located in Cambridge, MA.

Medcura, Inc. has developed an advanced wound care platform that can be used across a broad spectrum of clinical and non-clinical settings. By making molecular modifications to natural biopolymers, Medcura’s patented approach provides rapid hemostasis in a clean, safe healing environment. The company has achieved milestones such as 3 FDA Clearances, 6 issued patents, and 7 peer-reviewed publications.

Neumedicines Inc. is an emerging therapeutic biotechnology company focused on developing and commercializing innovative and proprietary products and approaches that address unmet clinical and societal needs in the areas of oncology, hematology, and immunology. The company operates from its headquarters in Pasadena, California. Neumedicines' lead product candidate is recombinant human interleukin-12 (rHuIL-12), a heterodimeric glycoprotein and cytokine. rHuIL-12 is being developed under the trade name HemaMax™ for various clinical indications, including hematopoietic syndrome of acute radiation syndrome (HSARS), skin cancers and other solid tumors, and blood disorders and malignancies.